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CASE PRESENTATION
A 50-year-old woman with type 2 diabetes mellitus
and hypertension was admitted to Brigham and Women’s
Hospital in Boston for entry into a clinical research pro-
tocol involving hemodynamic responses to angiotensin
II (Ang II) receptor blockade. She presented to a local
emergency room with severe headache at the age of 40.
Her blood glucose at that time exceeded 800 mg/dL. After
1 year of failed therapy with oral hypoglycemic agents, in-
sulin therapy was initiated. Her blood sugar control has
been fair; she complains of twice nightly nocturia. She
also has a burning and tingling neuropathy in her hands
and feet, and she suffers from migraines related to stress.
The patient’s mother and father both died from com-
plications of type 2 diabetes mellitus. One of her five sib-
lings has diabetes that is treated with oral medications.
The patient has three children who are well.
The medical history is significant for hypertriglyc-
eridemia and asthma; the most recent episode was 8 years
ago. She also has angina. Thallium perfusion imaging was
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performed for chest pain 2 years prior to admission; both
the stress and rest scan studies were normal. She had a
tubal ligation at age 35, gastric stapling, and a cholecystec-
tomy. Her current medications included lisinopril, 10 mg
daily (held for 2 weeks prior to physiologic study); insulin,
46 units NPH, 8 regular every morning; and 32 NPH, 6
regular each evening; gemfibrozil, 1200 mg daily; nizati-
dine, 150 mg twice daily; amitriptyline, 100 mg at bedtime
for neuropathy; and albuterol, 2 puffs as needed, but she
hasn’t required it in many months.
Physical examination revealed: height, 158 cm; weight,
106.2 kg. Her blood pressures while seated with a thigh
cuff were: 146/94 mm Hg, 144/94 mm Hg, and 146/94 mm
Hg. The standing blood pressure was 142/90 mm Hg;
pulse, 120 beats/min; and she reported feeling slightly
dizzy. Her heart rate was 100 beats/min. Examination of
the head, eyes, ears, nose, and throat was normal, with no
carotid bruits and no jugular venous distention. Cardiac
examination disclosed tachycardia, a regular S1 and S2,
and no murmurs. The patient was morbidly obese and
her abdomen was soft; bowel sounds were present. Her
lungs were clear, and there was no costovertebral angle
tenderness. No edema was present in her extremities.
Renal plasma flow (RPF) and glomerular filtration rate
(GFR) were determined under low-salt conditions (after
1 week of a 10 mmol Na+ diet) from the p-aminohippuric
acid (PAH) (Merck Sharp & Dohme, West Point, PA,
USA) and inulin clearances after achieving metabolic
balance on the low-salt diet. An intravenous catheter was
placed in each of the patient’s arms, one for the infu-
sion, the other for blood sampling. Basal PAH and inulin
clearances were calculated from their plasma levels and
infusion rates for each substance. Plasma samples reflect-
ing the control clearances were obtained 60 minutes af-
ter the start of the PAH infusion, when a steady state had
been achieved, and 90 minutes thereafter following treat-
ment with the Ang II type 1 (AT1) receptor antagonist
irbesartan.
Following 1 week on the low-salt diet, her basal plasma
renin activity (PRA) was 2.8 ng/Ang I/mL/hour and
her control arterial pressures during the equilibration
phase averaged 123/72 mm Hg. Following treatment with
150 mg of irbesartan, her arterial pressure fell slightly
to an average of 113/71 mm Hg. Basal RPF measured
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596 mg mL/min/1.73 m2. Ninety minutes after receiving
an acute dose of 150 mg irbesartan, the RPF was 786 mL/
min/1.73 m2, for a response to the angiotensin receptor
blocker of 190 mL/min/1.73 m2. The basal GFR was 122
mL/min/1.73 m2, and it increased to a peak GFR post
irbesartan of 163 mL/min/1.73 m2, for an increase of
41 mL/min/1.73 m2.
DISCUSSION
DR. L. GABRIEL NAVAR (Professor and Chairman,
Department of Physiology; and Co-Director, Hyperten-
sion and Renal Center of Excellence, Tulane University
School of Medicine, New Orleans, Louisiana, USA): This
patient is a dramatic example of a metabolic syndrome of
hypertension, diabetes, and obesity associated with hy-
pertriglyceridemia. Even though this woman does not
have severe hypertension, even moderately elevated ar-
terial pressure in patients with diabetes can pose seri-
ous long-term risks for target organ damage, including
the kidney. Treatment with angiotensin-converting en-
zyme (ACE) inhibitors or AT1 receptor blockers, how-
ever, can markedly retard the rate of loss of renal function
[1, 2]. She was given a low-salt diet for 1 week. Then an
acute dose of irbesartan, an Ang II AT1 receptor blocker
(ARB), was administered to determine the renal respon-
siveness to acute blockade of AT1 receptors. We should
note that this patient did not exhibit an unusually large
increase in PRA in response to the low-salt diet. Thus,
the circulating renin activity did not suggest a particu-
larly marked activation of the renin-angiotensin system
(RAS). Nevertheless, in response to acute treatment with
the ARB, she did manifest dramatic increases both in re-
nal plasma flow, measured by PAH clearance, and GFR,
measured by inulin clearance. This patient reflects a group
of individuals who might have marked activation of the
intrarenal RAS even though it is apparent neither from
the PRA data nor from the responses in systemic arterial
pressure to AT1 receptor blockade [3]. After 1 week of a
low-salt diet, this patient’s arterial pressure had fallen to
123/72 mm Hg the day of the study and only decreased
slightly in response to irbesartan treatment to 113/71 mm
Hg. Nevertheless, RPF increased by 32%, and the GFR
increased by 34%. Importantly, both the RPF and GFR
increased proportionally to a similar extent, leaving the
filtration fraction essentially unchanged (20% to 21%).
Similar results have been reported using ACE inhibitors,
ARBs, and renin inhibitors in normal subjects and in pa-
tients with essential hypertension [4–6].
Renal hemodynamic responses to Ang II
and Ang II blockade
On first impression, it would seem that this patient’s
response was paradoxical and at variance with the com-
monly held concept that high intrarenal Ang II levels pri-
marily constrict efferent arterioles, while ACE inhibitors
and ARBs primarily dilate efferent arterioles. This mis-
conception resulted from the generalization of the effects
of ACE inhibitors in patients with severe renal arterial le-
sions or stenosis or with long-standing structural damage
of the preglomerular arteriolar vasculature. When the
preglomerular vasculature loses its functional integrity,
blockade of the RAS system can lead to predominant
efferent arteriolar dilation and reductions in GFR. How-
ever, the bulk of the data both in patients and experimen-
tal animals indicates that Ang II elicits dose-dependent
decreases in RPF but often with lesser falls in GFR,
leading to increases in filtration fraction [7–9]. Likewise,
blockade of Ang II receptors raises both RPF and GFR
but decreases the filtration fraction [3, 7]. Unfortunately,
the Ang II-induced increases in filtration fraction and the
Ang II blockade-induced decreases in filtration fraction
frequently have been interpreted as evidence support-
ing a predominant effect of Ang II on efferent arteri-
oles. Let me emphasize that this interpretation is faulty
in that changes in filtration fraction often occur as a con-
sequence of parallel changes in afferent and efferent re-
sistances [8, 10]. A variety of studies both in normal and
hypertensive models have shown that Ang II elicits re-
ductions in single-nephron GFR and glomerular plasma
flow because Ang II increases both afferent and effer-
ent arteriolar resistances; direct microcirculation studies
have shown dose-dependent afferent and efferent arte-
riolar vasoconstriction elicited by Ang II [11, 12]. This
patient clearly demonstrated a robust increase in GFR as
well as in RPF in response to irbesartan. These increases
indicate that the preglomerular vasculature was highly
responsive, not functionally impaired, and was under the
substantial influence of high intrarenal levels of Ang II
that elicited strong influences on the renal microvascu-
lature. It is also possible that the increases in GFR were
partly due to (1) the ability of AT1 receptor blockade
to reverse Ang II-mediated decreases in the glomerular
filtration coefficient, and (2) to a component of plasma
flow dependency [3]. The estimated changes in the deter-
minants of glomerular dynamics are shown in Figure 1.
Although the magnitude of the increases observed is
greater than the responses generally observed, increases
in RPF and GFR have been reported often. Thus, one im-
portant objective of this Forum is to correct a commonly
held view that angiotensin antagonists predominantly di-
late the efferent arterioles.
The reason for the very robust responses to irbesar-
tan in certain patients is not clear, but it is assumed
that when intrarenal Ang II levels remain chronically
elevated, various compensatory mechanisms such as va-
sodilator prostanoids and intrarenal nitric oxide activity
are increased [13]. When the AT1 receptors were blocked
acutely, the stimulated vasodilatory mechanisms were left
1524 Nephrology Forum: Intrarenal angiotensin II in hypertension
RA
ΠG = 25
ΠI = 8
Πc = 37
ΠB < 1
EFP = 9
PB = 20
PI = 6
Pc = 20
RV
PG = 60 GFR = Kf 
.
 EFP
37
RE
Tubular
reabsorption
15
25
PCU = Kr . ERP
Control Irbesartan % Changes
RPF
GFR
FF .20 .21 +.05%
122 163 +34%
596 786 +32%
Fig. 1. Representative values for glomerular
and peritubular capillary dynamics in humans.
The increase in renal plasma flow (RPF) and
glomerular filtration rate (GFR) in response
to irbesartan observed in this patient can be
explained through a combination of decreases
in afferent as well as efferent arteriolar re-
sistance such that glomerular pressure is in-
creased along with increases in the glomerular
filtration coefficient (arrows). Assuming the
normal values shown in the figure and an in-
crease of Kf of 20%, the decreases in afferent
and efferent resistance would be estimated at
42% and 24%, respectively, to account for the
observed changes in RPF and GFR (for fur-
ther details on analysis, refer to [10]).
unopposed and markedly raised RPF and GFR [8]. With
continued treatment, the activity of these compensatory
mechanisms would be expected to abate and renal hemo-
dynamic function would return toward normal.
In general, elevated circulating renin levels in various
hypertensive and diabetic conditions are certainly recog-
nized as being indicative of a role for inappropriate acti-
vation of the RAS; but increased local activity of the RAS
can occur even when the circulating indices are within
the normal range. This increased activity could be due, in
part, to increased expression of ACE on renal vascular
endothelial cells in certain diseases, including diabetes
and hypertension [14]. In some organs, particularly the
kidneys and adrenal glands, intrarenal Ang II, expressed
as content per mass of tissue, is much greater than what
can be explained on the basis of passive equilibration
with the circulating components [15, 16]. In the case of
the kidney, the level of complexity might be even greater
than was previously thought in that there is specific com-
partmentalization of renin and angiotensin levels with
distinct regulatory mechanisms predominating in the sep-
arate compartments [17].
Studies in human subjects have provided support for
kidney-specific augmentation of the intrarenal RAS. In-
deed, some of the earliest reports of the effects of ACE
inhibition on renal function in humans demonstrated that
administration of the first ACE inhibitor known as tepro-
tide or SQ20881 to patients with essential hypertension
significantly increased GFR and sodium excretion de-
spite the associated decreases in arterial pressure [18].
Sodium excretion increased in every patient, and neither
the magnitude of the fall in blood pressure nor the change
in creatinine clearance influenced the degree of natriure-
sis. Patients with essential hypertension treated with cap-
tropril had a similar or greater natriuretic response [5].
These early findings set the stage for many subsequent
studies that led to the recognition that the natriuretic re-
sponses to ACE inhibitors cannot be explained solely on
the basis of the hemodynamic response but might include
direct changes in tubular sodium reabsorption. That the
responses to Ang II blockade in these patients could not
be correlated with plasma Ang II levels again suggested
independent regulation of intrarenal Ang II.
Several experimental models of hypertension support
an overactive RAS in the development and mainte-
nance of hypertension [7, 19, 20]. In Ang II-dependent
forms of hypertension, the inappropriate activation of
the intrarenal RAS limits the kidney’s ability to main-
tain sodium balance when perfused at normal arterial
pressures [7, 21]. Overactivation of the intrarenal RAS
leads to alterations in hemodynamic and transport func-
tion that contribute to the development and maintenance
of hypertension. Persistence of this overactivation leads
to long-term consequences, including cellular prolifera-
tion and renal injury.
Intrarenal Ang II receptors
The complex and extensive actions of Ang II on re-
nal function are mediated by the widespread distribu-
tion of Ang II receptors throughout the kidney in various
nephron segments as well as in the vasculature and inter-
stitium. The two major types of Ang II receptors are AT1
and AT2, but the hypertensinogenic actions of Ang II are
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Fig. 2. Angiotensin II (Ang II) receptor sub-
types and major renal actions attributed to ac-
tivation of AT1 and AT2 receptors. Rodents
appear to have two AT1 receptor subtypes,
but humans seem to have only one. Abbrevia-
tions are: Na, sodium; TGF, tubular glomeru-
lar feedback; ET, endothelin; TxA2, throm-
boxane A2; ICAM1, intercellular adhesion
molecule-1; MCP1, monocyte chemoattrac-
tant protein-1; IL-6, interleukin-6; TGFb ,
transforming growth factor beta; PAI-1,
plasminogen-activated inhibitor-1; NFjB, nu-
clear factor kappaB; RANTES, regulated
upon activation, normal T cell expressed and
secreted.
primarily attributed to the AT1 receptor because of its
multiple vascular and transport effects (Fig. 2). In addi-
tion to the vascular AT1 receptors, AT1 receptors have
been localized to glomerular podocyte cells, proximal
tubule brush border and basolateral membranes, inter-
stitial cells, thick ascending limb epithelia, distal tubules,
collecting ducts, and macula densa cells [22–24]. Because
of the extensive localization of AT1 receptors in luminal
as well as basolateral membranes of proximal and dis-
tal nephron segments, interest is growing in the relative
roles of Ang II in the renal interstitium and the tubu-
lar network. Much less AT2 receptor immunostaining oc-
curs in adult kidneys, but it has been found in proximal
tubules, collecting ducts, and some of the vasculature [23,
24]. Thus, it is now well recognized that Ang II has many
other actions in addition to the more obvious hemody-
namic responses. While some of these actions have ob-
vious physiologic relevance, others, such as activation of
cytokines and reactive oxygen species, occur primarily in
a pathophysiologic setting and are linked to tissue injury,
fibrosis, and proliferation [25]. In the final analysis, how-
ever, the local effects depend on the actual concentra-
tions of the Ang II maintained within the corresponding
compartment.
Intrarenal levels of Ang II
Although direct measurements in human subjects
are not available, experimental studies indicate that in-
trarenal Ang II tissue content is much higher than can
be explained on the basis of non-specific equilibration
between plasma Ang II concentrations and intrarenal
extracellular fluid [26–28]. Variations in dietary sodium
chloride intake are closely associated with changes in re-
nal renin, Ang I, and Ang II content. However, the total
renal levels of Ang I and Ang II remain higher than the
corresponding plasma concentrations, so the intrarenal
levels likely are not due to simple equilibration with cir-
culating Ang II [27–30].
Renal Ang II levels in several experimental models
of angiotensin-dependent hypertension are much higher
than the plasma concentrations. This has been demon-
strated in 2-kidney, 1-clip (2K1C) Goldblatt hyperten-
sion, Ang II-infused animals with hypertension, Ren2
TGR hypertension, and Dahl salt-sensitive rats fed a
high-salt diet [29–33]. In these models, the augmentation
of intrarenal Ang II content is the consequence of sev-
eral mechanisms. In addition to intrarenal formation of
Ang II, the kidney accumulates Ang II from the circula-
tion via an AT1 receptor-mediated process [31, 34]. Sus-
tained elevations in circulating Ang II cause progressive
accumulation of intrarenal Ang II levels even in the pres-
ence of marked suppression of renin formation. Of clini-
cal relevance is the finding that even non-clipped kidneys
of 2K1C Goldblatt rats have elevated intrarenal Ang II
levels. Increased Ang II levels occur in renin-depleted
kidneys of 2K1C Goldblatt hypertensive rats [29, 30, 35,
36], Ang II-infused hypertensive rats [29, 31], and Ren2
transgenic rats [33]. In Ang II-infused rats, the augmenta-
tion of intrarenal Ang II is dependent on an AT1 receptor-
mediated process, as it can be prevented by concomitant
treatment with AT1 receptor blockers [31, 34]. These data
demonstrate that intrarenal accumulation of Ang II oc-
curs via an AT1 receptor-mediated mechanism and sug-
gest the presence of receptor-mediated endocytosis and
the existence of an intracellular pool of Ang II [28].
Compartmentalization of intrarenal Ang II
The intrarenal content of Ang II is not distributed in a
homogeneous fashion but is compartmentalized in both
a regional and segmental manner [17]. Ang II levels in
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the deep medulla are much higher than cortical levels in
normal rats and increase further in Ang II-infused hyper-
tensive rats [15, 37]. Ang II in the renal medulla might be
particularly significant in regulating medullary hemody-
namics [38]. Also, Ang II receptor density is much greater
in the medulla than in the cortex [39].
Within the cortex, Ang II is distributed in the intersti-
tial and tubular fluid as well as within the cells. The in-
terstitial fluid contributes to the disproportionately high
total intrarenal Ang II levels. Studies using microdialy-
sis probes implanted in the renal cortex have shown that
Ang II and Ang I concentrations in interstitial fluid are
much higher than plasma concentrations [40, 41]. Renal
interstitial fluid Ang II concentrations were 3 to 5 pmol/
mL; Ang I concentrations were lower, in the range of
1 pmol/mL, but still much higher than the corresponding
plasma Ang I concentrations. Interestingly, in rat studies,
ACE inhibition was unable to lower the renal interstitial
Ang II concentrations significantly. This failure suggested
that much of interstitial Ang II is derived from sites not
readily accessible to ACE inhibitors [41]. As Figure 3 il-
lustrates, renal interstitial Ang II levels were significantly
elevated by about twofold in Ang II-infused rats, and this
increase was prevented by simultaneous treatment with
an AT1 receptor blocker, candesartan [42].
It is likely that interstitial Ang II is more important
in regulating hemodynamic and transport function than
is circulating Ang II [7]. Perfusion of Ang I and Ang II
into peritubular capillaries leads to infiltration into the
surrounding interstitium, afferent and efferent arteriolar
vasoconstriction, and decreases in single-nephron GFR.
Ang II in interstitial fluid might be principally responsi-
ble for maintaining tone of the pre- and post-glomerular
vessels and of influencing tubular transport function by
acting on Ang II receptors on the basolateral membranes
of the tubular cells. Interstitial Ang II also might be of
particular importance in regulating the sensitivity of the
tubuloglomerular feedback mechanism, which communi-
cates signals from the macula densa cells to the afferent
arterioles and which maintains a balance between filtered
load and the reabsorptive capabilities of the tubules [7,
43]. Thus, it is likely that in the patient being discussed,
the Ang II-dependent influences on vascular tone were
due primarily to the prevailing renal interstitial Ang II
concentrations and not to the plasma concentrations.
Intratubular Ang II
As I mentioned, Ang II receptors are present on the
luminal membranes of proximal and distal nephron cells.
Activation of these receptors stimulates the activity and
increases expression of the Na+/H+ exchanger in proxi-
mal and distal tubules, and also stimulates activity of the
sodium channel in the collecting duct; blockade of these
receptors reduces net sodium reabsorption [7, 44, 45].
0
2
4
6
R
IF
 A
ng
 II
, p
m
ol
/m
L *
0
100
200
300
400
Ki
dn
ey
 A
ng
 II
, f
m
ol
/g
0
100
200
300
400
500
600
Pl
as
m
a 
An
g 
II,
 fm
ol
/m
L
*
*
*
Vehicle-infused rats
Ang II-infused rats
Ang II-infused rats treated
with candesartan
Fig. 3. Renal interstitial fluid (RIF) angiotensin II (Ang II) concentra-
tions, renal Ang II levels, and plasma Ang II concentrations in control
rats, rats infused with Ang II for 2 weeks, and rats infused with Ang II
that also were treated with the AT1 receptor blocker candesartan. Ang
II-infused rats had an almost twofold increase in RIF Ang II, but this
increase was prevented by treatment with candesartan. The RIF Ang
II concentrations paralleled the renal Ang II contents and were disso-
ciated from the plasma Ang II concentrations, which increased further
with candesartan (from [42], with permission).
Another intriguing finding is that proximal tubule fluid
concentrations of Ang I and Ang II are in the range of
5–10 pmol/mL, much greater than the plasma concentra-
tions [16, 46, 47]. The finding that Ang II concentrations
in perfused tubules were similar to those measured in
non-perfused tubules demonstrated that the tubular fluid
Ang II concentrations are not derived from the glomeru-
lar filtrate [47]. Ang I and angiotensinogen (AGT), as well
as Ang II, are present in proximal tubular fluid. Thus,
intratubular Ang II could be formed from precursors
secreted into the tubular lumen. The various potential
pathways are depicted in Figure 4. It is interesting that
tubular fluid Ang II concentrations are not reduced in
several hypertensive models, including the non-clipped
kidney of the Goldblatt hypertensive rat, the Ren2 trans-
genic rat, and the Ang II-infused hypertensive rat as
compared to controls [33, 35, 48]. Considering that in all
these cases, the kidneys are markedly renin depleted and
exposed to elevated arterial pressures, the maintenance
of high proximal tubular Ang II concentrations reflects
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cretion, and uptake of angiotensin II (Ang II).
Ao, angiotensinogen. Summarized from data
presented in [15, 16, 35, 37, 41–44, 47, 48].
inappropriate intrarenal Ang II formation that might ex-
ert sustained effects on tubular transport function medi-
ating sodium reabsorption.
The Ang II concentrations in tubular fluid from other
segments of the nephron remain unknown due to tech-
nical difficulties of collecting sufficient volumes and to a
lack of access to these segments. However, studies sup-
port an important role for luminal Ang II in regulating
reabsorptive function in distal nephron and collecting
duct segments, as well as in proximal tubule segments [49,
50]. Ang II concentrations as low as 10 fmol/mL increase
distal tubular sodium transport [49, 50]. Studies by Peti-
Peterdi, Warnock, and Bell [51] have shown that Ang II at
1 pmol/mL stimulates sodium channel activity. Therefore,
the distal nephron represents a potentially important site
for further control of sodium transport regulation by
Ang II.
Endosomal accumulation of Ang II
The augmentation of intrarenal Ang II that occurs dur-
ing physiologic increases in angiotensin levels produced
by salt restriction or chronic infusion of Ang II includes
a component of AT1 receptor-mediated accumulation of
Ang II into an intracellular compartment [31, 34, 52].
The resultant increases in intracellular Ang II can serve
intracrine functions [53]. Haller et al [54] showed that
Ang II micro-injected into vascular smooth muscle cells
stimulates inositol trisphosphate (IP3) production via an
AT1 receptor-mediated action. In addition, endocytosis
of the Ang II-AT1 receptor complex, required for the
full expression of functional responses, is coupled to the
activation of signal transduction pathways and increased
sodium transport [55, 56]. A role for intracellular Ang II is
supported further by the demonstration that angiotensin
peptides, ACE, and Ang II receptors are present in renal
endosomes [28]. These results demonstrate that Ang II
is either formed or trafficked through intracellular endo-
somal compartments. Zhuo et al [57] demonstrated that
cortical endosomes, harvested after 2 weeks of Ang II
infusion in rats, exhibited marked increases in Ang II.
Concurrent treatment with the ARB candesartan pre-
vented the increases in endosomal, as well as total-kidney,
Ang II levels [57]. These data demonstrate increased
uptake and trafficking of Ang II into renal endo-
somes, mediated by AT1 receptors, in Ang II-dependent
hypertension.
The roles of the internalized Ang II remain unclear.
Several possibilities exist. As I said earlier, intracellular
Ang II might exert cytosolic actions. Ang II also could be
recycled and secreted to exert further actions by binding
to Ang II receptors on the cell membrane. A particu-
larly intriguing hypothesis is that Ang II might migrate
to the nucleus to exert transcriptional effects [58]. Chen
et al [58] transfected Chinese hamster ovary cells with
an AT1 receptor fused with green fluorescent protein,
which allowed visualization of trafficking of the inter-
nalized ligand-receptor complex. Ang II increased co-
localization of the green fluorescent protein with nuclear
markers, thus suggesting migration of the receptor com-
plex to the nucleus [58]. Recent studies demonstrated
specific nuclear Ang II binding in renal cortical cell sites
that is predominantly of the AT1 type [59]. Therefore,
direct Ang II actions intracellularly might include regu-
lation of nuclear signaling events.
Origins of intrarenal Ang II
The finding that renal interstitial fluid Ang II con-
centrations are much higher than plasma levels reflects
substantial interstitial Ang II formation. This is easily ex-
plained, as all the components needed for Ang II gen-
eration are present within the renal interstitium [7, 60].
Nevertheless, the mechanisms regulating renal interstitial
fluid Ang I and Ang II concentrations remain unclear.
Although it has generally been thought that interstitial
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AGT is of circulating origin, the finding of substantial
AGT mRNA and protein levels in renal proximal tubule
cells has raised the possibility that some of the interstitial
Ang II is derived from locally formed AGT and might
not be dependent on circulating Ang II or AGT [61–
63]. Nishiyama, Seth, and I [42] found that administering
AT1 receptor blockers to Ang II-infused rats prevented
not only the increase in total-kidney content but also the
increase in renal interstitial Ang II concentration, even
in the presence of elevated circulating levels. This find-
ing suggests that a substantial fraction of the interstitial
Ang II is formed from intrarenally produced AGT.
The localization of intrarenal AGT mRNA and protein
in proximal tubule cells indicates that proximal tubule
cells provide the substrate for intratubular and intersti-
tial Ang I and Ang II [64–67]. Importantly, AGT mRNA
levels and protein can be stimulated by Ang II. This para-
doxical positive amplification mechanism by which local
production of substrate is increased by its own prod-
uct likely contributes to the progressive increases in in-
trarenal production of Ang II in hypertension [61, 62, 68].
The AGT produced in proximal tubule cells might be di-
rectly secreted into the tubular lumen in addition to pro-
ducing its metabolites intracellularly and secreting them
into the tubular lumen [67, 69]. Proximal tubule AGT
concentrations in anesthetized rats approximate 300 nM,
greatly exceeding the free Ang I and Ang II tubular fluid
concentrations [15]. Because AGT’s molecular weight is
62,000 daltons, it seems unlikely that much of the plasma
AGT filters across the glomerular membrane. Thus, the
evidence indicates that AGT is secreted directly into the
tubular lumen [15, 67, 69–71]. Ang I then is formed in
the tubular lumen by renin or renin-like enzymes [64,
72]. In addition, cultured proximal tubule cells produce
renin and contain renin mRNA, so a low-level constitu-
tive renin secretion likely exists in proximal tubule cells
[64, 72, 73]. Once Ang I is formed, conversion to Ang
II readily occurs by the substantial ACE in the proxi-
mal tubule brush border and in the tubular fluid [74–76].
However, it remains unclear how much of the peptides
are formed intracellularly and how much are formed in
the tubular fluid.
Augmentation of intrarenal AGT production
Although increased intrarenal uptake of Ang II con-
tributes to the increased intrarenal Ang II in the Ang
II-infused model of hypertension, total intrarenal Ang II
levels are also due to additional intrarenal Ang II forma-
tion as a consequence of increased AGT production. In
vivo and in vitro studies have shown that Ang II stimu-
lates intrarenal AGT mRNA localized in proximal tubule
cells [61, 63, 68]. Furthermore, intrarenal AGT protein as
well as AGT mRNA levels increase in response to chronic
Ang II infusions [62]. This positive feedback system could
be responsible for sustained or increased generation of
AGT, which leads to continued intrarenal production of
Ang II. The intrarenally produced Ang II would be ad-
ditive with the Ang II that is internalized by the AT1 re-
ceptors and lead to the overall increase in intrarenal Ang
II contents. The presence of high concentrations of AGT
in proximal tubule fluid indicates substantial secretion
of AGT into the proximal tubule lumen. Furthermore,
the finding of intact AGT in urine suggests its presence
throughout the nephron and, to the extent that renin and
ACE are available along the nephron, there might be
continued Ang I generation and Ang II conversion in
segments beyond the proximal tubule [69, 71, 77].
Renin has been found on the luminal side of connect-
ing tubule cells in mouse and human kidneys; thus, renin
also might be secreted into distal tubular fluid [69]. AGT
has been detected at low nanomolar concentrations in
urine from mice and human volunteers, and mice given
low dietary salt intake had increased urinary AGT lev-
els [69]. Transgenic mice harboring the gene for human
AGT fused to the kidney androgen-protein promoter also
excreted human AGT in urine but it was not detected
in the systemic circulation [71]. Ang II-infused rats ex-
hibited an increase in AGT mRNA levels and intrarenal
AGT protein [62]. As Figure 5 shows, chronic Ang II
infusions also led to marked increases in urinary AGT
excretion rates in association with the increases in sys-
tolic blood pressure [78, 79]. Furthermore, there was a
direct relationship between urinary AGT excretion rates
and renal Ang II contents [78, 79]. The increased urinary
AGT was specifically associated with Ang II-dependent
hypertension and was not simply due to hypertension-
induced proteinuria. These data thus support the concept
that angiotensin-dependent hypertension is accompanied
by increased AGT secretion by the proximal tubule cells,
which leads to spillover of intact AGT into distal nephron
segments. Because distal tubule cells have available renin
and ACE or other enzymes that can subserve similar
functions, the expected result is increased distal tubular
formation of Ang II and increased Ang II-dependent
stimulation of the distal sodium reabsorption rate [51].
This increase in distal sodium reabsorption might help ex-
plain the markedly increased fractional sodium reabsorp-
tion and suppression of pressure natriuresis that occurs in
Ang II-infused rats [80]. Thus it seems likely that urinary
AGT concentrations or excretion rates reflect the distal
nephron spillover of AGT and, accordingly, provide an
index of the magnitude of the increased intrarenal AGT
production in angiotensin-dependent hypertension.
From a functional perspective, the additive effects of
Ang II working on distal nephron transport function cou-
pled with the associated actions of elevated aldosterone
levels markedly increase the sodium-retaining ability
of the kidney which, when inappropriately sustained,
contributes to the development and maintenance of
hypertension. Furthermore, these sustained increases in
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Fig. 5. Urinary angiotensinogen (AGT) excretion rates and systolic
blood pressures (BP) in control rats and rats infused with Ang II at two
rates, 40 ng/min and 80 ng/min (from [79], with permission).
intrarenal Ang II in a setting of hypertension produce
progressive renal injury and cellular proliferation asso-
ciated with activation of several major cytokines and
growth factors [25].
QUESTIONS AND ANSWERS
DR. NICOLAOS E. MADIAS (Dean ad Interim, Tufts
University School of Medicine, Boston, Massachusetts):
You described the effects of exogenous Ang II infusion
on intrarenal AGT and Ang II. What about the effects
of endogenous increases in systemic Ang II as a result of
volume depletion or other states of secondary hyperal-
dosteronism (that is, congestive heart failure, cirrhosis)?
DR. NAVAR: We do not have data on hyperaldostero-
nism or volume depletion. However, there are data re-
garding changes during physiologic manipulation of the
RAS, such as with differences in salt intake. In a setting
like that, we and others have observed parallel changes
in circulating as well as intrarenal renin levels. With a
low-salt diet, there is a marked stimulation of plasma
renin, plasma Ang II, and renal Ang II levels [28, 52].
However, the renal Ang II levels expressed per gram of
kidney weight are still much higher than the plasma con-
centrations. Under these conditions, the circulating and
renal levels change in a parallel manner, and it’s very hard
to determine how much of the change that occurs in the
kidney is due to intrarenal formation and how much is
due to delivery from the plasma.
An important difference is that during physiologic
stimulation of the RAS, neither hypertension nor re-
nal injury occurs. This suggests that other factors associ-
ated with the development of hypertension facilitate the
Ang II internalization as well as the injury that occurs.
DR. MADIAS: What do we know about the mecha-
nism of entry of AGT from the proximal tubule cell into
the lumen? Also, you showed a correlation between uri-
nary AGT and intrarenal Ang II. What about measuring
Ang II itself in the urine?
DR. NAVAR: Ang II is formed and degraded rapidly.
Ang II in the urine might be derived from the circulation
or the kidney, so it is not possible to determine the source
of the Ang II. In contrast, AGT is a large molecule, so
very little, if any, crosses the glomerular membrane [70].
Because practically none of the circulating AGT appears
in the urine [79], urinary AGT is probably all of intrarenal
origin. That’s why we use AGT as a reflection of intrarenal
formation. In terms of the actual mechanism of secretion,
it is an exocytotic mechanism, but we have not looked
at specific, targeted mechanisms by which the AGT is
secreted in the proximal tubule.
DR. MADIAS: Can you exclude the possibility that
part of the AGT measured in the urine reflects degrada-
tion fragments of systemic AGT that were filtered at the
glomerulus?
DR. NAVAR: We have used infusions of human AGT
to determine how much circulating AGT appears in the
urine. We assayed for human AGT in both plasma and
urine in rats infused with human AGT [79]. We did not
find human AGT either intact or in immunoreactive frag-
ments in either normal control rats or Ang II-infused rats.
That’s the only study we have done, but I think that fur-
ther studies are necessary in this area.
DR. RONALD PERRONE (Division of Nephrology,
Tufts-New England Medical Center, Boston, Mas-
sachusetts): In Boston, we’ve been extensively exposed to
the concept of efferent arteriolar vasoconstriction in pro-
gressive kidney disease. How would you integrate your
findings into this model, that is, an increased intrarenal
production of Ang II causing efferent arteriolar vaso-
constriction? ACE inhibitors have slowed progression of
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renal disease in rat models and in human disease. What
happens where there’s intrarenal production of Ang II?
Does that also lead to uptake and increased production of
AGT? Are angiotensin receptor blockers more effective
than ACE inhibitors in inhibiting Ang II in the kidney?
DR. NAVAR: Let me address your last question first.
From what we know of the differences in actions be-
tween ACE inhibitors and Ang II receptor blockers, one
would expect to see greater differences in the responses
observed. However, experimental studies and clinical tri-
als have failed to show any major differences in responses.
The key lies in the differences between therapeutic doses
as compared to the doses used experimentally. The doses
used therapeutically just diminish the level of activity
rather than completely block Ang II actions or circulat-
ing concentrations. Thus, it is difficult to discriminate be-
tween the effects of ACE inhibition and those of Ang II
receptor blockade in patients.
With regard to the other point, it was originally thought
that almost everything related to hypertension-induced
renal injury could be explained on the basis of altered re-
nal hemodynamics. We now know that Ang II stimulates
many other factors, as highlighted recently [25]. Various
cytokines that might or might not have effects on renal
hemodynamics are activated. Some of these are involved
in long-term injury and proliferative responses and have
important roles.
With regard to the effects of Ang II on afferent and
efferent arteriolar resistances, I emphasized that the
often-stated concept that Ang II only constricts effer-
ent arterioles is simply not true under most conditions.
Ang II clearly exerts vasoconstrictor actions both on af-
ferent and efferent arterioles. Thus, ACE inhibitors and
Ang II receptor blockers do vasodilate afferent as well
as efferent arterioles, but the important point is that the
efferent action helps protect against unusually large in-
creases in glomerular pressure under conditions of renal
vascular dilation. Clearly, if you compare calcium channel
blockers with either ACE inhibitors or Ang II receptor
blockers, the calcium channel blockers primarily dilate
afferent arterioles. For any given level of arterial pres-
sure, the effects of calcium channel blockers would be
associated with a much greater degree of glomerular hy-
pertension than are the ACE inhibitors.
Unfortunately, the concept often transmitted to stu-
dents is that Ang II only affects the efferent arterioles.
If this were true, every patient taking an ACE inhibitor
or a receptor blocker would go into acute renal failure.
All you have to do is drop glomerular pressure a few
millimeters of mercury to drastically reduce GFR. The
important message to emphasize is that Ang II has com-
bined effects on both pre- and post-glomerular arterioles.
Because the structural integrity of efferent arterioles is
protected in many kinds of injury mechanisms to a greater
extent than is that of the pre-glomerular vasculature, in
certain diseases associated with pre-glomerular vascular
disease, the pre-glomerular arterioles become unrespon-
sive. Thus, a patient with severe arteriolar damage might
have unresponsive pre-glomerular arterioles that are no
longer functionally intact. This can lead to a situation in
which only the efferent arterioles respond to antagonism.
DR. D. PAK: You suggested that calcium channel block-
ers and ACE inhibitors have different actions on afferent
and efferent arterioles. Would this combination be good
for our patients?
DR. NAVAR: Some studies have shown that the combi-
nation of a calcium channel blocker with either an ACE
inhibitor or an Ang II receptor blocker would be syn-
ergistic and could provide added benefit. Experimental
studies have shown that L-type calcium channel blockers
produce predominantly afferent vasodilation with negli-
gible efferent effects and can elevate glomerular pressure.
Thus it would be beneficial to combine a calcium chan-
nel blocker with an Ang II antagonist. Calcium channel
blockers have a more powerful natriuretic effect and a
more powerful ability to dilate vascular smooth muscle
throughout the body, so a physician might choose to give
a calcium channel blocker. However, the addition of an
ACE inhibitor or Ang II receptor blocker would provide
added benefit by directly blocking Ang II’s effects on ef-
ferent arterioles and by inhibiting the effects of Ang II
on tubular transport.
DR. MADIAS: What have we learned about AGT and
systemic blood pressure from gene-targeting studies or
genetic studies in humans?
DR. NAVAR: Studies in humans based on the genetic
analysis of large populations and analysis of polymor-
phisms have provided mixed results [70]. As reviewed
by Lalouel et al [81], the results from studies of renin
and ACE have been inconclusive. However, significant
genetic linkage observed for AGT [81] suggested that in-
dividual differences in the AGT gene might contribute to
disease development. The studies done in gene-targeted
mice, in particular by Oliver Smithies’ group, clearly show
that hypertension is a function of the level of expression
of the AGT gene [82]. The four-copy AGT mice have
much higher blood pressures than do the zero-copy ani-
mals. Smithies emphasized that, in contrast to the ACE
gene, under- and overexpression of AGT clearly projects
changes in blood pressure. What is needed now is more
extensive studies of renal function in the mice overex-
pressing and underexpressing AGT.
DR. MADIAS: Are the changes in the intrarenal RAS
also reflected in other tissue renal-angiotensin systems,
for example, that of the heart or the adrenal gland?
DR. NAVAR: The only organs with clear indications
of abundant local generation of Ang II are the kid-
neys and adrenal glands. The adrenal glands have very
high Ang II and renin levels. Because the adrenal glands
are so small, however, it is unlikely that adrenal renin
contributes very much to the circulating renin. Neverthe-
less, as Dzau [83] and others have emphasized for many
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years, Ang II is formed locally in many tissues, and com-
ponents of the RAS are present in tissues throughout
the body, including the brain, heart, and vasculature, es-
pecially under conditions where there is injury. However,
the circulating renin levels are derived almost exclusively
from the kidneys. John Laragh has emphasized this point
many times. If the kidneys are removed, renin levels be-
come undetectable within 48 hours.
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